div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 10button div class=ts-image amp-img class=ts-thumb alt=Page 10: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails10jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 11button div class=ts-image amp-img class=ts-thumb alt=Page 11: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails11jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 12button div class=ts-image amp-img class=ts-thumb alt=Page 12: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails12jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 13button div class=ts-image amp-img class=ts-thumb alt=Page 13: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails13jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 14button div class=ts-image amp-img class=ts-thumb alt=Page 14: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails14jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 15button div class=ts-image amp-img class=ts-thumb alt=Page 15: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails15jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 16button div class=ts-image amp-img class=ts-thumb alt=Page 16: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails16jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 17button div class=ts-image amp-img class=ts-thumb alt=Page 17: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails17jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 18button div class=ts-image amp-img class=ts-thumb alt=Page 18: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails18jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 19button div class=ts-image amp-img class=ts-thumb alt=Page 19: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails19jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 20button div class=ts-image amp-img class=ts-thumb alt=Page 20: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails20jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 21button div class=ts-image amp-img class=ts-thumb alt=Page 21: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails21jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 22button div class=ts-image amp-img class=ts-thumb alt=Page 22: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails22jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 23button div class=ts-image amp-img class=ts-thumb alt=Page 23: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails23jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 24button div class=ts-image amp-img class=ts-thumb alt=Page 24: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails24jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 25button div class=ts-image amp-img class=ts-thumb alt=Page 25: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails25jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 26button div class=ts-image amp-img class=ts-thumb alt=Page 26: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails26jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 27button div class=ts-image amp-img class=ts-thumb alt=Page 27: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails27jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 28button div class=ts-image amp-img class=ts-thumb alt=Page 28: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails28jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 29button div class=ts-image amp-img class=ts-thumb alt=Page 29: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails29jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 30button div class=ts-image amp-img class=ts-thumb alt=Page 30: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails30jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 31button div class=ts-image amp-img class=ts-thumb alt=Page 31: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails31jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 32button div class=ts-image amp-img class=ts-thumb alt=Page 32: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails32jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 33button div class=ts-image amp-img class=ts-thumb alt=Page 33: Treatment of the high CV risk patients: Current global · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10305 hypertensive patients randomized to src=https:reader030vdocumentinreader030viewer20220406175f1c3f5e181a075cce4e7092html5thumbnails33jpg width=142 height=106 layout=responsive amp-img divdiv